We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · September 23, 2021

Maintenance With Daratumumab or Observation Following Induction Treatment and Auto-SCT in Patients With Newly Diagnosed Multiple Myeloma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Lancet Oncol 2021 Sep 13;[EPub Ahead of Print], P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj, L Benboubker, MC Béné, S Zweegman, H Caillon, D Caillot, J Corre, M Delforge, T Dejoie, C Doyen, T Facon, C Sonntag, J Fontan, M Mohty, KS Jie, L Karlin, F Kuhnowski, J Lambert, X Leleu, M Macro, F Orsini-Piocelle, M Roussel, AM Stoppa, NWCJ van de Donk, S Wuillème, A Broijl, C Touzeau, M Tiab, JP Marolleau, N Meuleman, MC Vekemans, M Westerman, SK Klein, MD Levin, F Offner, M Escoffre-Barbe, JR Eveillard, R Garidi, T Ahmadi, M Krevvata, K Zhang, C de Boer, S Vara, T Kampfenkel, V Vanquickelberghe, J Vermeulen, H Avet-Loiseau, P Sonneveld

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.